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Issues related to HIV/AIDS in prisons have tra-
ditionally received little attention at the
International AIDS Conference. Yet, it is a well-
known fact that HIV prevalence within prison
populations tends to be much higher than in
the general population both in the United
States and worldwide. This year's conference,
"AIDS 2004," held in Bangkok, Thailand, (July
11-16) may, however, represent a turning
point. Before the official conference started, a
one-day satellite meeting debated issues relat-
ed to HIV/AIDS in prisons in great depth. At
the conference itself, two oral sessions and a
large number of poster presentations were
dedicated to HIV/AIDS in prisons. In addition,
three United Nations agencies released an
important policy brief on reduction of HIV
transmission in prisons. Although most activi-
ties focused on HIV prevention, delegates also
debated the question of how HIV treatment,
including antiretrovirals (ARVs), can best be
made available to inmates. This was particu-
larly important in light of current efforts spear-
headed by the World Health Organization to
make effective treatments available to three
million people in developing countries by
2005.1 While it is impossible to provide a
detailed overview of all the prison-related
developments presented at AIDS 2004, this
article will first provide some background infor-
mation on HIV/AIDS in prisons worldwide, and
then highlight some of the relevant findings
presented at the conference. 
HIV/AIDS IN PRISONS WORLDWIDE
HIV Prevalence
In most countries, prevalence of HIV infection
within prison populations is much higher than
i  the general population, with some countries
reporting rates in the range of 10 to 25 per-
cent.2 The jurisdictions with the highest HIV-
prevalence within prisons are those where
rates of HIV infection among injection drug
users (IDUs) are high, as this group is dramat-
ically over-represented in correctional institu-
tions.
HIV Transmission in Prison
Incarceration has been associated with HIV
infection in several countries,3 including
Thailand, where the first wave of HIV infec-
tions occurred in 1988 among IDUs. From a
negligible percentage at the beginning of the
year, the infection rate among IDUs rose to
over 40 percent by September, fueled in part
by transmission of the virus as many IDUs
moved in and out of penal institutions.4 A
more recent study concluded that IDUs in
Bangkok continue to be "at significantly
increased risk of HIV infection through sharing
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needles with multiple partners while in
holding cells before incarceration."5
Additional evidence for rapid HIV trans-
mission in prisons was documented in
Scotland in 1993.6 Among 227 Scottish
inmates participating in a study of HIV risk
behavior and infection at Glenochil institu-
tion, 76 (33 percent) reported a history of
injection, and 33 (43 percent) of those
individuals reported injecting while in the
prison. Thirty-two (97 percent) of those
who admitted to injecting in prison also
reported sharing syringes. Of the 162 indi-
viduals who were tested for HIV, twelve (7
percent), tested positive for HIV antibod-
ies. All of these individuals had reported
injecting while in the prison. Evidence
derived from serial HIV testing and prison
admission records confirmed that at least
eight of these inmates contracted HIV dur-
ing the first six months of 1993. 
Another example of a documented out-
break occurred in a prison in Lithuania.
During random checks undertaken in
2002 by the state-run AIDS Center, 263
prisoners at Alytus prison tested positive
for HIV antibodies. Tests at Lithuania's
other 14 prisons, which house 11,700 con-
victs, found only 18 cases of HIV infection.
Before the tests at Alytus prison,
Lithuanian officials had listed only 300
cases of HIV infection in the whole coun-
try, or less than 0.01 percent of the popu-
lation, the lowest prevalence in Europe. It
is believed that the outbreak at Alytus
prison was also due to sharing of drug
injection equipment.7
HIV Risk Behaviors
Despite the sustained efforts of prison
systems to prevent drug use by prisoners,
the reality is that drugs can and do enter
prisons. Many inmates come to prisons
with their drug habits already established.
In fact, many inmates are sentenced in
the first place because of drug-related
crimes. People who used drugs outside
often find a way to continue drug use on
the inside. Others start using drugs in
prison as a way to release tensions and to
cope with being in an overcrowded and
often violent environment.8
Studies have shown that ongoing injection
drug use is also prevalent in prisons in
many countries.9 As in the United States,
imprisonment is a common event for IDUs
worldwide. In a 12-city World Health
Organization study of HIV risk behavior
among IDUs, between 60 and 90 percent
of respondents reported a history of
imprisonment since commencing drug
injection.10 For IDUs who continue to use
while incarcerated, imprisonment increas-
es the risk of contracting blood-borne
infections, including HIV and hepatitis C
virus (HCV) and hepatitis B virus (HBV).
This is because those who inject drugs in
prison almost always share needles and
syringes. IDUs have contributed to signifi-
cant risk-reduction in the community
through introduction of a variety of mea-
sures that include needle exchange, edu-
cation, and provision of treatment. On the
other hand, risk behavior in prisons (with
the exception of prisons that have intro-
duced the preventive measures described
below) has remained unchanged over the
last decade.11 In one Australian study, six
of the 36 participants who reported inject-
ing and sharing needles when last in
prison also reported that it was the first
time they had ever shared syringes.12
Most often, only a handful of needles will
circulate among a large population of pris-
oners who inject drugs. 
Because sharing of injection equipment is
inherently a high-risk activity, and in some
prisons a more common occurrence, sex-
ual activity is considered to be a less sig-
nificant risk factor in prisons for HIV and
HCV transmission. Nevertheless, it does
occur and puts prisoners at risk of con-
tracting HIV infection. Homosexual activi-
ty occurs inside prisons, as it does out-
side, as a consequence of sexual orienta-
tion. In addition, prison life produces con-
ditions that encourage homosexual activi-
ty and the establishment of homosexual
relationships between inmates who do not
identify themselves as homosexuals. The
prevalence of sexual activity in prison is
based on such factors as whether the
accommodation is single-cell or dormitory,
the duration of the sentence, the security
classification, and the extent to which con-
jugal visits are permitted. Studies of sexu-
al contact in prison have shown "inmate
involvement to vary greatly."13
Responses of Prison Systems
Initially, response to the issues raised by
HIV/AIDS, HCV, and drug use in prisons
was slow. In many prison systems world-
wide, only small steps were made to
develop policies and to provide education-
al programs for staff and prisoners.
However, in recent years a growing num-
ber of prison systems have started adopt-
ing a pragmatic, public health approach to
HIV/AIDS. These systems are making
condoms, bleach and even sterile injec-
tion equipment and methadone mainte-
nance treatment available, in addition to
providing substance abuse treatment and
educational programs delivered or supple-
mented by community-based outside
organizations and/or peers.
Responding to Injection Drug Use
Recognizing that drugs, needles, and
syringes permeate the most secure of
prison walls, and while continuing and
often stepping up drug interdiction efforts
and substance abuse programs, prison
systems around the world are taking steps
to reduce the risk of the spread of HIV and
other diseases. Some of these measures
are not necessarily easy to implement,
and there are legal, ethical, as well as
practical problems associated with them.
These steps have usually been undertak-
en as a pilot project, but their success to
date has led to their continuation, and
indeed extension into other prisons and
other countries.14
One strategy to reduce the risk of HIV
transmission through the sharing of injec-
tion equipment is to provide liquid bleach
to sterilize needles and syringes. Already
in 1991, 16 of 52 prison systems surveyed
in Europe made bleach available to pris-
oners.15 Significantly, no system that has
adopted a policy of making bleach avail-
able in penal institutions has ever
reversed the policy, and the number of
systems in Europe that make bleach
available has continued to grow every
year.16 Bleach is also available in many
other prison systems, including in most
Canadian prisons17 and in many prisons in
Australia.18
While making bleach available to inmates
may reduce the spread of HIV from injec-
tion drug use in prisons, sterile, never-
used needles and syringes are safer than
bleach-disinfected, previously-used nee-
dles and syringes.19 The probability of
effective decontamination is decreased
further in prison. Because prisoners can
be discovered at any moment by prison
staff since injecting and cleaning is a hur-
ried affair. Studies have shown that bleach
disinfection takes more time than most
2
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3prisoners allow. In addition, even when
bleach is provided, prisoners may find it
difficult to access.20 Finally, bleach is not
fully effective in killing HCV.21
Therefore, an increasing number of
prison systems have introduced needle
exchange or distribution programs.
Outside prisons, in many countries such
programs have become an integral part of
a pragmatic public health response to the
risk of HIV transmission among IDUs (and
ultimately, to the general public).
Extensive studies on the effectiveness of
these programs have been carried out.
For many years, there has been scientifi-
cally sound evidence showing that they
are an appropriate and important preven-
tive health measure.22
Introducing needle exchange programs in
prisons has been recommended.23 At
AIDS 2004, the first comprehensive sur-
vey of the experience with existing prison-
based needle exchange programs was
presented (see below). 
Finally, worldwide, an increasing number
of correctional systems have introduced
methadone maintenance treatment
(MMT). Outside prisons, MMT programs
have rapidly expanded in many countries
over the last decade. There are ample
data supporting their effectiveness in
reducing high-risk injecting behavior and
in reducing the risk of contracting HIV.
There is also evidence that MMT is a high-
ly effective treatment available for heroin-
dependent IDUs in terms of reducing mor-
tality, heroin consumption, and criminality.
Further, MMT attracts and retains more
heroin injectors than any other form of
treatment. Finally, there is evidence that
people who are on MMT and who are
forced to withdraw from methadone
because they are incarcerated often
return to narcotic use, often within the
penal institutions, and often via injection.24
As in the community, MMT, if made avail-
able to prisoners, has the potential of
reducing injecting and syringe sharing in
prisons. Evaluations of MMT programs in
prisons have shown positive results. For
example, in Canada, the federal prison
system expanded access to MMT after
evaluation demonstrated that MMT has a
positive impact on release outcome and
on institutional behavior.25
Preventing sexual transmission of HIV
Many prison systems worldwide are also
making condoms available to prisoners. In
1991, 23 of the 52 European prison sys-
tems surveyed allowed condom distribu-
tion.26 Making condoms available has not
resulted in any significant security prob-
lems,27 and no system that has adopted a
policy of making condoms available in
prisons has reversed the policy. The num-
ber of systems that make condoms avail-
able has continued to grow every year.
For example, in a number of surveys
undertaken in Europe, the proportion of
prison systems that made condoms avail-
able rose from 53 percent in 1989 to 75
percent in 1992 and 81 percent in 1997. In
the most recent survey, condoms were
available in all but four systems.28 In 1995
in Australia, 50 prisoners launched a legal
action against the state of New South
Wales (NSW) for non-provision of con-
doms, arguing that "[it] is no proper part of
the punishment of prisoners that their
access to preventative means to protect
their health is impeded."29 Since then, at
least in part because of the legal action,
the NSW government has decided
to make condoms available. Other
Australian systems, most Canadian sys-
tems, a growing number of facilities in the
U.S. and elsewhere also make condoms
available.
AIDS 2004 HIGHLIGHTS
The Satellite Conference on HIV/AIDS
in Prisons
A one-day pre-conference seminar, which
brought together 150 people from many
different countries and backgrounds,
debated issues related to HIV/AIDS in
prisons at great length. Entitled "Human
Rights at the Margins: HIV/AIDS,
Prisoners, Drug Users and the Law," and
organized by a group of organizations
including the Canadian HIV/AIDS Legal
Network and UNAIDS, the conference
provided an overview of the state of the
HIV/AIDS epidemic in prisons worldwide.
Also discussed were responses by prison
systems; key public health, human rights,
legal and ethical issues; and recommen-
dations about how to increase HIV educa-
tion, prevention, care, treatment and sup-
port efforts in prisons worldwide. A back-
ground paper prepared for the conference
argues that increased efforts are neces-
sary not only for public health reasons, but
are required by international law. With
regard to availability of prevention mea-
sures, the paper states:
"Measures undertaken to prevent the
spread of HIV and other infections will
benefit prisoners, staff, and the public.
They will protect the health of prisoners,
who should not, by reason of their impris-
onment, be exposed to the risk of a dead-
ly condition. They will protect staff: lower-
ing the prevalence of infections in prisons
means that the risk of exposure to these
infections will also be lowered. They will
protect the public. Most inmates are in
prison only for short periods of time and
are then released into their communities.
In order to protect the general population,
prevention measures need to be available
in prisons, as they are outside." 31
With regard to treatment, the paper
argues that in high income countries, the
right to enjoyment of the highest attain-
able standard of physical and mental
health, in concert with the principle of
equivalence, dictates that inmates should
have access to a high standard of care,
including specialist consultation, diagnos-
tic testing (CD4, viral load, viral resis-
tance) and the full range of ARVs licensed
for sale within a particular country.32 The
paper is currently being finalized based on
feedback received at the conference and
peer review."33
Oral Sessions on HIV/AIDS in Prisons
at AIDS 2004
The first of two major oral sessions on
HIV/AIDS in prisons was entitled, "Not
hard-to-reach, but still hard-to-serve?
What works in HIV prevention and care in
prisons." It included presentations from
prison officials from Indonesia,34
Thailand,35 and Iran,36 as well as a pre-
sentation on the first comprehensive sur-
vey of prison-based needle exchange pro-
grams.37 The presenter from Thailand
focused on his country's efforts to deal
with the problem of TB and HIV coinfec-
tion in prisons. The officials from
Indonesia and Iran discussed the mea-
sures, including condoms, bleach, and
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4MMT, that have been introduced in their
countries to respond to HIV/AIDS in pris-
ons. It was encouraging to hear senior offi-
cials speak openly about heavily stigma-
tized and prohibited behaviors such as
injection drug use and homosexual activity,
and discuss the pragmatic response to pre-
vent the greater evil: the spread of HIV
among inmates and ultimately to the com-
munity. While Indonesia and Iran have not
yet introduced prison-based needle
exchange programs, other countries such
as Switzerland, Germany, Spain and an
increasing number of countries in Eastern
Europe have. The survey of such programs
that was presented at the session revealed
that a steadily increasing number of pris-
ons have established and evaluated needle
and syringe exchange or distribution pro-
grams. All evaluations of such programs
have been favorable. In particular, they
have shown improvement in the health of
prisoners and reduction of syringe sharing.
Feared negative consequences have not
materialized: needles have not been used
as weapons, and there has been no report-
ed increase in drug consumption. The pre-
sentation concluded that prison-based nee-
dle exchange programs have proven safe
and effective, and the presenters opined
that there remain no valid reasons not to
introduce them in other prison systems.38
The second oral session was entitled
"Preventing HIV spread in prisons" and
included presentations from the U.S.,
Canada, Pakistan, and Thailand:
Barry Zack from California presented on
the role of non-governmental organizations
(NGOs) as partners of prison systems in
the fight against HIV/AIDS.39 He empha-
sized that a unique opportunity for collabo-
ration exists between penitentiaries and
NGOs when it comes to the provision of
prevention, social support and transitional
HIV services for inmates. He concluded
that "prison officials who have worked with
NGOs have shown that the collaboration
can work for the prison, the NGO, the pris-
oner and the community."
Richard Wolitski presented the results of
"Project START," funded by CDC to devel-
op an HIV, STD, and hepatitis prevention
program for young men aged 18-29 who
are leaving prison and to test the effective-
ness of a number of interventions in reduc-
ing sexual risk after leaving prison. Results
showed that those prisoners who received
enhanced interventions consisting of two
pre-release, four post-release, and optional
sessions based on participant need were
less likely to engage in unprotected sex
than prisoners who only received a single
pre-release session intervention.40
A Canadian study showed that of 1,475
IDUs enrolled in the Vancouver Injection
Drug Users Study (VIDUS), 1,123 (76 per-
cent) reported a history of incarceration
since they first began injecting drugs. Of
these, 351 (31 percent) reported, via inter-
views, ever injecting in prison. Among all
those interviewed, including those with and
without HIV infection, incarceration during
the six months prior to the interview was
associated with syringe borrowing during
that period. The researchers concluded
that "incarceration was independently
associated with risky needle sharing for
HIV-infected and HIV-negative IDUs," and
that the "strong evidence of HIV risk behav-
ior should reinforce public health concerns
about blood-borne diseases transmission
in prisons."41
Both the presentations from Pakistan42
and Thailand43 focused on the growing
population of children and juveniles in pris-
ons, and emphasized the need for pro-
grams aimed at reducing their vulnerability
to HIV/AIDS. 
A New Resource
A final important development at AIDS
2004 was the release of a policy brief on
reduction of HIV transmission in prisons by
three United Nations agencies (the World
Health Organization, UNAIDS, and the UN
Office on Drugs and Crime).44 Consistent
with the message of the satellite confer-
ence and most oral presentations at AIDS
2004, the document calls upon govern-
ments to step up HIV prevention measures
in prisons by adopting comprehensive pro-
grams that include all the measures
against HIV transmission that are carried
out in the community, including needle
exchange. It concludes with the following
"policy and programming implications":
The prevention of HIV transmission in pris-
ons is mostly hampered by the denial of
governments of the existence of injection
drug use and sexual intercourse in prisons,
rather than by a lack of evidence that key
interventions work. There is ample evi-
dence that drug use in general, injecting
drug use in particular, and sexual inter-
course among inmates are widespread in
such institutions. Furthermore, there are
data indicating that the risk of HIV infection
i  prisons is usually higher than in the gen-
eral community. Once this has been
accepted, governments have a wide range
of program options for preventing HIV
ransmission in prisons.
The evidence shows that such programs
should include all the measures against
HIV transmission, which are carried out in
the community outside prisons, including
HIV/AIDS education, testing and counsel-
ing performed on a voluntary basis, the dis-
tribution of clean needles, syringes and
condoms, and drug-dependence treat-
ment, including substitution treatment. All
these interventions have proved effective in
reducing the risk of HIV transmission in
prisons. They have also been shown to
have no unintended negative conse-
quences. The available scientific evidence
suggests that such interventions can be
reliably expanded from pilot projects to
nationwide programs.45 At the end of the
conference, some delegates expressed
satisfaction that issues surrounding
HIV/AIDS in prisons are starting to receive
the attention they deserve. The hope is that
by the time of the next International AIDS
Conference, to be held in Toronto, Canada
in 2006, the world will have better appreci-
ated and responded to the reality of
HIV/AIDS in prisons.
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Dear Correctional Colleagues:
Many of us didn't make the International AIDS Conference in Bangkok this year. If you're
like me and feel remorse over missing out on International AIDS issues, you read any
updates you can get your hands on to try and assuage your guilt. This month's Bangkok
Conference Update by Ralf Jürgens discusses HIV prevention efforts, such as condom dis-
tribution; AIDS service organizations and CBO involvement in corrections; HIV/AIDS coun-
seling and testing; needle-exchange programs (NEPs) and provision of bleach for steriliza-
tion of shared injector equipment in prisons; and methadone maintenance programs
(MMPs). Indeed, it was nice to see different parts of the world catching up. 
At Rikers, our MMP requires patients to be involved in methadone maintenance on the out-
side and to qualify by criminal charges before continuation of methadone. We implement
methadone detoxification for heroin-addicted patients experiencing withdrawal and for
patients being transferred to prison facilities where methadone is not continued. Many of us
see methadone utilization as compassionate care with the now acknowledged benefit of
discouraging needle sharing.
I had a hard time imagining our jail actually implementing NEPs in prisons and provision of
bleach for sterilization of shared injector equipment. I read with interest the recognized real-
ization that injector equipment is considered contraband and there are security concerns
regarding its use as weapons. Now I'm reminded we'rebehind. 
The importance of prison/jail HIV/AIDS issues cannot be over-emphasized. The reality that
jails and prisons are a significant part of communities is clear and undeniable. Learning that
other countries grapple with these issues, and that some go leagues beyond us in their
interventions, is heartening even for those institutions that have implemented different
strategies to diminish the spread of HIV within corrections, and hopefully influence safer
behavior outside our walls. It helps to remind us of why we have these critical prevention
efforts to begin with. I once read that a prison system in Scotland actually provides a
"shoot-up gallery" for their inmates. Now that's really thinking outside the box.
Karl Brown, MD FACP
Infectious Diseases Supervisor- Rikers Island
LETTER FROM THE EDITOR
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7The fifteenth International AIDS Conference held in Bangkok was
the largest AIDS conference in history. Almost 20,000 individuals
from 152 countries attended this conference and presented 8,641
abstracts in five distinct tracks. These included basic science, clin-
ical care, social and economic issues, epidemiology and preven-
tion and policy and program implementation. While there was con-
siderable interest in all of the above-mentioned areas, this article
will focus solely on the clinical care track in order to provide new
information that may be used for the care of HIV-infected patients
in the correctional system.  
Several studies were presented that used existing licensed anti-
retroviral therapy (ART).  In the CONTEXT study, PI-experienced
patients (patients who failed one or two PIs previously) were ran-
domized to receive one of two ritonavir boosted PI treatments:  fos-
amprenavir (f-APV) vs. lopinavir (LPV). All subjects must have had
a viable nucleoside analogue backbone available to them using
resistance testing. There were two f-APV arms: 700mg/100mg BID
and 1400mg/200mg QD. The once-daily f-APV arm was discontin-
ued prematurely because of low efficacy outcomes, suggesting
that for PI-experienced patients, f-APV should be administered
twice-daily. The primary 48-week outcomes demonstrated similar
efficacy between the f-APV and LPV arms with a mean VL reduc-
tion of 1.49 and 1.76 log, respectively. The proportion with a VL<50
was 46% and 50%, respectively.1
Three studies addressed the concern about renal toxicity in
patients receiving tenofovir (TDF). These studies range from very
healthy antiretroviral naïve patients without baseline renal insuffi-
ciency to patients with preexisting renal disease. In the pivotal GS
903 trial that compared TDF to D4T in healthy ART-naïve patients
receiving EFV+3TC, patients receiving TDF were no more likely to
have laboratory changes in creatinine, phosphorus, proteinuria or
glycosuria after three years.2 An evaluation of Kaiser Permanente
patients in five clinical care settings where 199 subjects received
TDF for at least three months, subtle mean increases in creatinine
were noted, however no increase in phosphaturia or proteinuria
was noted.3 In a case control study of patients with mild renal insuf-
ficiency, 74 patients that received TDF were compared to 84
patients who did not. Patients with other known causes for renal
insufficiency were excluded (e.g., diabetes, hypertension). The
proportion with a decreased GFR (34% vs. 21%) and proteinuria
(36% vs. 16%) was higher among those receiving TDF compared
to those not on TDF.4 These data suggest that TDF rarely causes
renal toxicity in patients without underlying renal disease. For
those with baseline renal disease, renal disease remains uncom-
mon. Renal function, however, should be carefully monitored.  
Another study clearly established the inferiority of triple NRTI ther-
apy. The ESS40013 study examined 448 ART-naïve patients who
had a sustained VL<50 copies/mL at the end of 48 weeks after
receiving the four-drug combination of AZT/3TC/ABC+EFV.
Patients were randomized to either reduce their regimen to
AZT/3TC/ABC or continue with AZT/3TC/ABC+EFV. Patients were
followed for an additional 48 weeks.  Efficacy measured by VL<50
was equivalent for both groups (77% vs. 79%), however subjects
receiving AZT/3TC/ABC were more likely to have virological failure
(16% vs. 8%) and less likely to experience medication toxicity (6%
vs. 15%) than patients continuing on the four-drug regimen. These
data suggest that virological potency is low in patients receiving
triple nucleoside therapy, even in patients who were successfully
inducing using a potent four-drug regimen that initially included
EFV.5
New data from BMS 045 were presented in highly ART-experi-
enced patients randomized to ATV/r vs. LPV/r.  Efficacy regarding
reduction in VL was equivalent between the two groups, however
metabolic complications were reduced in patients receiving ATV/r.
M tabolic syndrome was diagnosed (Metabolic syndrome: abdom-
inal obesity, TGs >150 mg/dL, BP (>30 mm Hg systolic or >85
diastolic), fasting glucose >110 mg/dL, low HDL (<40 mg/dL in
men, <50 mg/dL in women)) in 20% of LPV/r patients, compared
to 10.7% of ATV/r patients and more patients receiving LPV/r initi-
ation lipid-lowering medications (17.9% vs. 7.5%).6
The use of LPV/r was found to be associated with increased hepa-
toxicity in patients coinfected with either HBV or HCV in 816
patients in eight clinical trials. Patients with HBV/HCV coinfection
had imilar virological and immunological response rates as those
with viral hepatitis, however the proportion with ALT >5 times the
pper limit of normal was 16% compared to only 5% in patient
without HBV/HCV. Death (1-2%) and discontinuation of medication
due to adverse side effects (7%) did not differ between those with
and without HBV/HCV infection.7
I po tant new data regarding pregnancy and HIV treatment were
available. The complications of pregnancy were evaluated in 472
patients at one U.S. medical center from 1985 to 2003.  Dramatic
increase in preeclampsia (0.4% to 6.4%) and fetal death (0% to
4.2%) in 2001-2003 period compared to earlier time periods when
less than three combination therapies were used. The only factor
associated with this increased morbidity was duration of HAART
therapy.  Fortunately, there were no HIV transmissions in the most
recent time period suggesting that HAART markedly reduces HIV
tran mission, however at increased risk for women on prolonged
therapy.  
Two studies examined pharmacokinetics of ART therapy in preg-
nant women in the third trimester.  LPV levels (AUC and Cmin) in
hird trimester were significantly lower during the third trimester
than in post-partum and historical controls. Ten out of the 12
women studied did not meet the target AUC exposure, suggesting
the need for increased dosing. Until data are available using
increased doses, LPV/r should not likely be used during this time
period, and if it is, it should be used with guidance from therapeu-
tic drug monitoring.8 In another study, NVP AUC levels were
decreased with pregnancy, however the Cmin was not adversely
affected.  This suggests that NVP may be used in pregnancy, but
used with extreme caution in women with higher CD4 counts.9
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Infectious Disease Society of
America
September 30 - October 3, 2004
Boston, MA
www.idsociety.org
ProVisions IX, the Northeast
Multicultural Conference on
HIV/AIDS
October 13 - 15, 2004
New Haven, CT
Call: Carla Giles, Program
Committee Co-Chair
203.688.3184
Email: Carla.Giles@ynhh.org or
Leif.Mitchell@yale.edu.
Visit: www.provisionsct.org
Chest 2004
October 23 - 28, 2004
Seattle, WA
Call: 847.498.1400
Fax: 800.343.2227 
Visit:www.chestnet.org/CHEST/
program/index.php. 
Practical Management of HIV:
A One Day Regional
Workshop Covering the
Practical Aspects of HIV
Management 
October 25, 2004
Sturbridge, MA
Call AAHIVM: 310.278.6380 or
NEAETC: 617.262.5657
Visit: www.aahivm.org or
www.neaetc.org.
44th Annual ICAAC
October 30 - November 2, 2004
Washington, DC
Call: 800.974.3621
Visit: www.asm.org
7th International Conference
on Healthcare Resource
Allocation for HIV/AIDS 
October 3 - 4, 2004
Washington, D.C.
Visit: www.iapac.org 
HIV Mini-fellowship Program
November 8, 9, 10, 2004
University of Texas Medical
Branch, Galveston, TX
Call Victoria Korschgen:
409.772.8799
Email: vikorsch@utmb.edu
SAVE THE
DATES
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FDA Approves Truvada™
(One Pill Once Daily) 
Gilead Sciences recently announced that the
FDA has approved Truvada™ (emtricitabine
and tenofovir disoproxil fumarate), a fixed-dose
combination of the company's anti-HIV medica-
tions of Emtriva® and Viread®. Truvada™ com-
bines 200 mg of emtricitabine and 300 mg of
tenofovir disoproxil fumarate in a single tablet,
taken once daily in combination with other anti-
retroviral agents, potentially making it easier to
construct convenient combination regimens. 
Press Release, Gilead Sciences, August 2,
2004.
FDA Approves Epzicom™ 
(One Pill Once Daily)
Epizcom™, a new product by GlaxoSmithKline
combining two HIV medicines into one tablet
dosed once a day with no food or fluid require-
ments, was recently cleared for prescription use
by the FDA. Epzicom™ combines two widely-
used nucleoside reverse transcriptase inhibitors
(NRTIs), Epivir® (lamivudine, 3TC) and
Ziagen® (abacavir sulfate, ABC) for use in com-
bination with other antiretroviral drugs.
Epizicom™ tablets are recommended for use in
combination with antiretroviral drugs from differ-
ent pharmacological classes and not with other
nucleoside/nucleotide reverse transcriptase
inhibitors. 
Press Release, GlaxoSmithKline, August 2,
2004.
Invirase® 500 mg Tablet Granted FDA
Priority Review
Roche announced that the FDA has granted pri-
ority review status to the New Drug Application
(NDA) for a 500 mg tablet formulation of its HIV
protease inhibitor, Invirase® (saquinavir mesy-
late). If approved, the new formulation of
Invirase may simplify dosing regimens by reduc-
ing pill count for each dose by more than half
(from five pills to two, twice-daily). Ritonavir
should be taken at the same time as Invirase.
Invirase and ritonavir should be taken within two
hours after a meal.
Press Release, Roche, August 17, 2004.
Study: High prevalence and late diagnosis
of HIV among Black men aged 40-54 in NYC
Of 40-54-year-old Black males living with
HIV/AIDS (PLWHA) diagnosed since June 2000
(n=1,523), nearly one in three had concurrent
HIV/AIDS (31.4% of new HIV diagnoses)
according to a study reported at the Bangkok
International AIDS Conference. Since New York
City began HIV reporting in June 2000, non-
Hispanic Black men have comprised the largest
group of PLWHA and new HIV and AIDS diag-
noses. Prevalence among Black men varies by
age and geography, as do concurrent HIV/AIDS
diagnoses, suggesting barriers to access to
testing and care. The authors concluded that
prevalence of HIV/AIDS is high in Black men
aged 40-54, particularly in Manhattan, while
Brooklyn has the greatest number of PLWHA.
The high rate of concurrent diagnoses in 40-54
y ar-old Black male PLWHA, especially among
those born outside the U.S., indicates that many
were long-infected but not tested until sympto-
matic. Late diagnosis may delay entry to prima-
ry care and preventive counseling.
NATAP - www.natap.org
Study: Prednisone Ineffective Against HIV-
Associated Pleural Tuberculosis
Prednisone, a glucocorticoid that is sometimes
added to anti-tuberculosis drug regimens,
should not be used to treat HIV-infected patients
who have pleural tuberculosis, nor is it recom-
mended for those with pleural tuberculosis who
are not coinfected with HIV, according to a
recent study. In a double-blind, placebo-con-
trolled study of prednisolone in 197 patients with
HIV-1-associated pleural tuberculosis.
Investigators found that the drug had no effect
on survival but did increase the risk of AIDS-
related cancer Kaposi's sarcoma. This recom-
mendation does not extend to other uses of
prednisolone, such as treatment of pericardial
tuberculosis or Pneumocystis carinii pneumo-
nia, for which the drug can prolong or save lives,
regardless of the patient's HIV status. 
The Journal of Infectious Diseases, August 5,
2004.
IN THE NEWS
RESOURCES
Official online abstracts of the XV International AIDS Conference published by eJIAS:
www.aids2004.org
Information on prison-based needle exchange programs:
http://www.aidslaw.ca/Maincontent/issues/prisons.htm
Information on harm reduction in prisons:
www.aidslaw.ca/Maincontent/issues/prisons/NEP_150604.PDF
Updated series of 13 info sheets on HIV/AIDS in prisons:
www.aidslaw.ca/Maincontent/infosheets.htm#isohaap
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To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through March 31, 2005. 
The estimated time for completion of this activity is one hour and there is no fee for participation.
1. Correctional systems that have implemented condom distribution
and/or needle exchange have:
a) Experienced a surge in use of condoms and needles as 
weapons
b) Increased HIV transmission among inmates
c) Frequency of rape among inmates
d) None of the above
2. According to the World Health Organization study of risk behavior
among injection drug users (IDUs), over half of respondents reported
a history of imprisonment since commencing drug injection. True or
False.
a) True
b) False
3. Outside prisons, the implementation of needle exchange or distrib-
ution programs is:
a) Supported by evidence showing that they are an 
appropriate and important public health measure 
b) Recognized by the CDC as one component of a 
pragmatic public health response to the risk of HIV 
transmission among IDUs
c) Mentioned in a policy brief by three United Nations 
agencies as a means of stepping up HIV prevention 
measures in prisons
d) All of the above
4. According to a recent study, the percentage of European prison
systems that make condoms available to inmates is closest to:
a) 0
b) 25
c) 50
d) 100
5. All of the following statements are true except:
a) Methadone maintenance treatment (MMT) is a highly 
effective treatment for heroin-dependent IDUs in terms of 
reducing mortality, heroin consumption, and criminality.
b) MMT may increase high-risk injecting behavior and the 
spread of HIV in prisons.
c) The Canadian federal prison system expanded access to 
MMT after demonstrating that it has a positive impact on release 
outcome and institutional behavior.
d) People who are on MMT prior to incarceration and who are 
then forced to withdraw from methadone because they are 
incarcerated often return to narcotic use within the correctional 
system.
6. Studies have shown that among IDUs, incarceration leads to a
decreased risk of needle-sharing behavior. True or False.
a) True
b) False
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